Home
Conditions
Hemostatic Disorders

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,080 public trials 582 recruiting studies

Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00536601

Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), +137 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Completed

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

NCT02104427

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +17 more
Locations: Stony Brook University Hospital Stony Brook, New York, United States

Tennessee Oncology, PLLC Nashville, Tennessee, United States

View Trial Details

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

NCT01458288

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations: Stony Brook University Hospital Stony Brook, New York, United States

View Trial Details

Completed

Standing Cognition and Co-morbidities of POTS Evaluation

NCT03602482

Conditions: Autonomic Nervous System Diseases, Cardiovascular Diseases, Collagen Diseases, +19 more
Locations: Penn State College of Medicine Hershey, Pennsylvania, United States

View Trial Details

Completed

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

NCT02112175

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour Baudour, Belgium

AZ-VUB Brussels, Belgium

Grand Hopital de Charleroi Charleroi, Belgium

Universitair Ziehenhuis Antwerpen Edegem, Belgium

View all 73 locations

View Trial Details

Completed

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

NCT00858234

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Not specified

View Trial Details

Completed

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

NCT01045460

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States

View Trial Details

Completed

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

NCT04439214

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +23 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Completed

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

University Of Arkansas Little Rock, Arkansas, United States

Scripps Clinic Torrey Pines La Jolla, California, United States

UC Davis; Comprehensive Cancer Center Sacramento, California, United States

View all 31 locations

View Trial Details

Completed

Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)

NCT00773838

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations: Not specified

View Trial Details

Hemostatic Disorders

Hemostatic Disorders trial results

Related conditions